Novo Nordisk stock price sinks nearly 18% as 2026 outlook jolts Wegovy trade
Novo Nordisk shares fell about 18% in Copenhagen after the company warned of a possible 5–13% drop in 2026 sales and profit, citing U.S. price cuts and rising competition. The drugmaker faces pressure from cheaper copycat obesity drugs and a leadership change in its U.S. unit set for Feb. 5. U.S.-listed shares dropped 14.2% Tuesday.